MACH7 TECHNOLOGIES LIMITED — Capital/Financing Update 2016

Aug 3, 2016

ASX Announcement

4 August 2016

==> picture [610 x 89] intentionally omitted <==

Mach7 Signs Distribution Agreement to Accelerate Sales Growth in Europe

Summary:

• Rotterdam-based Alphatron Medical Systems appointed as distributor

• Focus on the Netherlands, Belgium and Luxembourg

• Benelux countries have one of the largest healthcare spends in Europe

Melbourne, Australia; 4 August 2016: Mach7 Technologies Limited ( Mach7 or the Company ) (ASX: M7T ), a global provider of enterprise imaging solutions, today announced it has entered into a distribution Agreement ( Agreement ) with Alphatron Medical Systems B.V. ( Alphatron ) for the distribution of Mach7 Technologies™ Enterprise Imaging Platform throughout the Netherlands, Belgium and Luxembourg ( Territory ).

The Territory comprises the Benelux countries of the Netherlands, Belgium and Luxembourg which has a combined population of 28.5 million people and, according to EuroStat, has some of the highest healthcare spending as a percentage of GDP of any of the countries in continental Europe.

Under the terms of the Agreement, Alphatron will market and distribute the full Mach7 suite of enterprise imaging solutions, including their industry leading Mach7 Enterprise Imaging Platform. Alphatron will additionally provide user training and customer support throughout the Territory.

Mach7 works with a limited number of distributors to assist the Company in rapidly accelerating its global sales strategy. Rotterdam-based Alphatron is best positioned to promote, sell and service Mach7 in the Benelux due to its demonstrated experience as an electronic equipment and software distributor and reseller, particularly in medical workstations and enterprise PACS (Picture Archiving and Communication Systems), and domain expertise.

Harald Verloop, director Alphatron Medical, commented, “we have observed the Mach7 solution in action and have spoken to our customers. Mach7’s technologies complement and extend our product portfolio for our customers. We look forward to collaborating with this recognised industry leader to service our customers and improve patient care.”

Reuven Soraya, senior vice president, international sales at Mach7, commented, “we are delighted to partner with Alphatron to bring our value to the hospitals and health care delivery organisations in the Benelux. Alphatron is highly respected by their customers, and we are looking forward to serve this thriving market together with Alphatron.”

-ENDS

==> picture [610 x 123] intentionally omitted <==

ASX Announcement

4 August 2016

==> picture [610 x 89] intentionally omitted <==

About Alphatron:

Rotterdam-based Alphatron was established in the 1970s and focuses on developing, producing and trading in electronics through specialised divisions for shipping, broadcasting, security, medical and industry sectors. Alphatron has nearly 300 employees across more than 25 offices on four continents including Asia, the Americas, Europe and Australia & New Zealand. Visit www.alphatron.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimised vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit www.mach7t.com

Mach7’s wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical’s innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit www.3dmedical.com.au

Contacts:

Albert Liong Jenni Pilcher CEO CEO Australia, CFO +1 650 743 0167 (U.S.) +61 3 9646 2222 (Australia) albert.liong@mach7t.com jenni.pilcher@mach7t.com

Julia Vaughn Investor Relations +1 802 768 0143 (U.S.) julia.vaughn@mach7t.com

==> picture [610 x 123] intentionally omitted <==